Download PDF
Exp Clin Endocrinol Diabetes 2004; 112(2): 102-107
DOI: 10.1055/s-2004-815765
Article

J. A. Barth Verlag in Georg Thieme Verlag Stuttgart · New York

Urinary 6-Sulfatoxymelatonin Excretion in Hyperandrogenic Women: The Effect of Cyproterone Acetate-Ethinyl Estradiol Treatment

R. Luboshitzky1 , P. Herer2 , Z. Shen-Orr3
  • 1Endocrine Institute, Haemek Medical Center, Afula, Israel
  • 2B. Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel
  • 3Endocrine Laboratory, Rambam Medical Center, Haifa, Israel
Further Information

Publication History

Received: October 24, 2002 First decision: March 17, 2003

Accepted: August 25, 2003

Publication Date:
19 March 2004 (online)

Also available at
    Permissions and Reprints

Abstract

Evidence for a relationship between melatonin and the reproductive hormones in humans is based on observations of abnormal melatonin secretion in clinical disorders of the pituitary-gonadal axis. The aim of this study was to investigate melatonin production in hyperandrogenic women before and during treatment with cyproterone acetate and ethinyl estradiol (Diane 35). Twelve women with polycystic ovary syndrome (PCOS), 10 women with idiopathic hirsutism (IH), and 10 women with late onset adrenal hyperplasia due to 21-hydroxylase deficiency (LOCAH) were studied. Patients were treated with Diane 35 for four months. Fasting blood samples for the determination of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone and dihydroepiandrosterone sulfate (DHEAS) and 24-hour urine collections for the determination of 6-sulfatoxymelatonin (aMT6s) excretion were obtained from all patients at baseline and after 4 months of treatment. Results were compared with those obtained in 15 control women. At baseline, women with PCOS and LOCAH had significantly higher testosterone and aMT6s values than women with IH and controls. Diane 35 treatment significantly decreased testosterone, LH, FSH and aMT6s values in PCOS and LOCAH patients compared with pretreatment values.

These results indicate that hyperandrogenic women with PCOS and LOCAH have increased melatonin production. The decrease in aMT6s excretion together with reduced serum LH, FSH, DHEAS and testosterone values during treatment with cyproterone acetate-ethinyl estradiol, suggest that sex steroids either directly or through the suppression of gonadotropins, modulate melatonin secretion in these patients.

Key words

Melatonin - cyproterone acetate - estradiol - androgens - polycystic ovary syndrome

References

  • 1 Blaicher W, Imhof M H, Gruber D M, Schneberger C, Sator M O, Huber J C. Endocrinological disorders focusing on melatonin interactions.  Gynecol Obstet Invest. 1999;  48 179-182
    CrossrefPubMedGoogle Scholar
  • 2 Bojkowski C J, Arendt J. Factors influencing 6-sulphatoxymelatonin - a major melatonin metabolite in normal human subjects.  Clin Endocrinol. 1990;  33 435-444
    CrossrefPubMedGoogle Scholar
  • 3 Brosen K. Drug interactions and the cytochrome P450 system. The role of cytochrome P4501A2.  Clin Pharamacol. 1995;  29 20-25
    PubMedGoogle Scholar
  • 4 Brzezinski A, Seibel M M, Lynch H J, Deng M H, Wurtman R J. Melatonin in human preovulatory follicular fluid.  J Clin Endocrinol Metab. 1987;  64 865-867
    PubMedGoogle Scholar
  • 5 Brzezinski A, Lynch H J, Seibel N M, Deng M H, Wurtman R J. The circadian rhythm of plasma melatonin during the normal menstrual cycle and in amenorrheic women.  J Clin Endocrinol Metab. 1988;  66 891-895
    PubMedGoogle Scholar
  • 6 Caglayan S, Ozata M, Ozisik G, Turan M, Bolu F, Ontenli C, Arslan N, Erbil K, Gul D, Ozdemir I C. Plasma melatonin concentration before and during testosterone replacement in Klinefelter's syndrome: Relation to hepatic indolamine metabolism and sympathoadrenal activity.  J Clin Endocrinol Metab. 2001;  86 738-743
    CrossrefPubMedGoogle Scholar
  • 7 Cardinali D P, Nagle C A, Rosner J M. Control of estrogen and androgen receptors in the rat pineal gland by catecholamine transmitter.  Life Sci. 1975;  16 93-106
    CrossrefPubMedGoogle Scholar
  • 8 Cardinali D P, Vacas M I, Keller-Sarmiento M I, Etchegogen G S, Pereyra E N, Chalayan H E. Neuroendocrine integrative mechanisms in mammalian pineal gland: effect of steroid and adenohypophyseal hormones on melatonin synthesis in vitro.  J Steroid Biochem. 1987;  27 565-571
    CrossrefPubMedGoogle Scholar
  • 9 Delfs T M, Baarks S, Fock C, Schumacher M, Olcese J, Zimmerman R C. Sex steroids do not alter melatonin secretion in humans.  Hum Reprod. 1994;  9 49-54
    PubMedGoogle Scholar
  • 10 Falsetti L, Gaubera A, Tisi G. Efficacy of the combination ethinyl estradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovary syndrome.  Hum Reprod. 2001;  16 36-42
    CrossrefPubMedGoogle Scholar
  • 11 Fruzetti F, Bersi C, Parrini D, Ricci C, Genazzani A R. Treatment of hirsutism: comparisons between different antiandrogen with central and peripheral effects.  Fertil Steril. 1999;  71 445-451
    CrossrefPubMedGoogle Scholar
  • 12 Itoh M T, Ishizuka B, Kudo Y, Fusama S, Amemiya A, Sumi Y. Detection of melatonin and serotonin N-acetyltransferase and hydroxyindole-O-methyltransferase activities in rat ovary.  Mol Cell Endocrinol. 1997;  136 7-13
    PubMedGoogle Scholar
  • 13 Kadva A, Djahanbakach O, Monson J, Di W L, Silman R. Elevated nocturnal melatonin is a consequence of gonadotropin-releasing hormone deficiency in women with hypothalamic ammenorrhea.  J Clin Endocrinol Metab. 1998;  83 3653-3662
    CrossrefPubMedGoogle Scholar
  • 14 Kovacs J, Brodner W, Kirchlechner V, Arif T, Waldhauser F. Measurement of urinary melatonin: A useful tool for monitoring serum melatonin after its administration.  J Clin Endocrinol Metab. 2000;  85 666-670
    CrossrefPubMedGoogle Scholar
  • 15 Leibenluft E, Schmidt P J, Turner E H, Danaceau M A, Ashman S B, Wehr T A, Rubinow D R. Effects of leuprolide-induced hypogonadism and testosterone replacement on sleep, melatonin and prolactin secretion in men.  JClin Endocrinol Metab. 1997;  82 3203-3207
    PubMedGoogle Scholar
  • 16 Luboshitzky R, Lavi S, Thuma I, Lavie P. Testosterone treatment alters melatonin concentrations in male patients with gonadotropin-releasing hormone deficiency.  J Clin Endocrinol Metab. 1996 a;  81 770-774
    CrossrefPubMedGoogle Scholar
  • 17 Luboshitzky R, Wagner O, Lavi S, Herer P, Lavie P. Decreased nocturnal melatonin secretion in patients with Klinefelter's syndrome.  Clin Endocrinol. 1996 b;  45 749-754
    CrossrefPubMedGoogle Scholar
  • 18 Luboshitzky R, Dharan M, Goldman D, Herer P, Hiss Y, Lavie P. Seasonal variation of gonadotropin and gonadal steroid receptors in the human pineal gland.  Brain Res Bull. 1997;  44 665-670
    CrossrefPubMedGoogle Scholar
  • 19 Luboshitzky R, Lavie P. Melatonin and sex hormones interrelationships - a review.  J Pediatr Endocrinol Metab. 1999;  12 355-362
    PubMedGoogle Scholar
  • 20 Luboshitzky R, Levi M, Shen-Orr Z, Blumenfeld Z, Herer P, Lavie P. Long-term melatonin administration does not alter pituitary-gonadal hormone secretion in normal men.  Hum Reprod. 2000 a;  15 60-65
    CrossrefPubMedGoogle Scholar
  • 21 Luboshitzky R, Shen-Orr Z, Ishai A, Lavie P. Melatonin hypersecretion in male patients with adult-onset idiopathic hypogonadotropic hypogonadism.  Exp Clin Endocrinol Diabetes. 2000 b;  108 142-145
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Luboshitzky R, Shen-Orr Z, Nave R, Lavi S, Lavie P. Melatonin administration alters semen quality in healthy man.  J Androl. 2002;  23 547-554
    PubMedGoogle Scholar
  • 23 Mathews C D, Guerin M V, Wang X. Human plasma melatonin and urinary 6-sulphatoxymelatonin: studies in natural animal photoperiod and in extended darkness.  Clin Endocrinol. 1991;  35 21-27
    PubMedGoogle Scholar
  • 24 Okatani Y, Sagara Y. Amplification of melatonin secretion in women with functional secondary ammenorrhea: relation to endogenous oestrogen concentration.  Clin Endocrinol. 1994;  41 766-780
    PubMedGoogle Scholar
  • 25 Oriola J, Plesa I, Machuca I, Pavia C, Rivera-Fillat F. Rapid screening method for detecting mutations in the 21 hydroxylase gene.  Clin Chem. 1997;  43 557-561
    PubMedGoogle Scholar
  • 26 Ozata M, Bulkur M, Bingal N, Beyhan Z, Corakci A, Bolu E, Gundogan M D. Daytime plasma melatonin levels in male hypogonadism.  J Clin Endocrinol Metab. 1996;  81 1877-1881
    CrossrefPubMedGoogle Scholar
  • 27 Paoletti A M, Cagnacci A, Orru M, Ajossa S, Gueriero S, Melis G B. Treatment with flutamide improves hyperinsulinemia in women with idiopathic hirsutism.  Fertil Steril. 1999;  72 448-453
    CrossrefPubMedGoogle Scholar
  • 28 Rajmil O, Puig-Domingo M, Tortosa F, Viader M, Patterson A G, Schwarzstein D, DeLeiva A. Melatonin concentration before and during testosterone replacement in primary hypogonadic men.  Eur J Endocrinol. 1997;  137 48-52
    CrossrefPubMedGoogle Scholar
  • 29 Rittmaster R S. Antiandrogen treatment of polycystic ovary syndrome.  Endocrinol Metab Clin North Am. 1999;  28 409-421
    CrossrefPubMedGoogle Scholar
  • 30 San Martin A, Bogdan A, Touitou Y. Day-night differences in the effects of gonadal hormones on melatonin release from perifused rat pineals. Evidence of a circadian control.  Steroids. 1996;  61 27-32
    CrossrefPubMedGoogle Scholar
  • 31 Shurtz E G, Brimer C, Shuetz J D. Environmental xenobiotics and the antihormone cyproterone acetate and spironolactone use the nuclear hormone pregnenolone X receptor to activate the CYP3A23 hormone response element.  Mol Pharamacol. 1998;  54 1113-1117
    PubMedGoogle Scholar
  • 32 Skene D J, Papagiannidou E, Hashemi E, Snelling J, Lewis D F, Fernandez M, Joannides C. Contribution of CYP1A2 in the hepatic metabolism of melatonin: studies with isolated microsomal preparations and liver slices.  J Pineal Res. 2001;  31 333-342
    CrossrefPubMedGoogle Scholar
  • 33 Stefukj J, Hortner M, Ghosh M, Schauenstein K, Rinner I, Wolfler A, Semmler J, Liebmann P M. Gene expression of the key enzymes of melatonin synthesis in extrapineal tissues of the rat.  J Pineal Res. 2001;  30 243-247
    CrossrefPubMedGoogle Scholar
  • 34 Ursing C, Hartter S, Von Bahr C, Tybring G, Bertilsson L, Rojmarl K. Does hepatic metabolism of melatonin affect the endogenous serum melatonin level in men?.  J Clin Invest. 2002;  25 459-462
    PubMedGoogle Scholar
  • 35 Venturoli S, Marescalchi O, Colombo F M, Marcelli S, Ravaioli B, Bagnoli A, Paradisi R, Flamigni C. A prospective study randomized trial comparing low dose Flutamide, Finesteride, Ketoconazole, and Cyproterone Acetate-Estrogen regimens in the treatment of hirsutism.  J Clin Endocrinol Metab. 1999;  84 1304-1310
    CrossrefPubMedGoogle Scholar
  • 36 Voordouw B GG, Euser R, Verdonk R ER, Alberda B J, DeJong F H, Drojendijk A C, Fauser B C, Cohen M. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation.  J Clin Endocrinol Metab. 1992;  74 108-117
    CrossrefPubMedGoogle Scholar
  • 37 Waldhauser F, Frisch H, Krautgasser G A, Sparotti A, Schober E, Bieglmayer C. Serum melatonin is not affected by glucocorticoids replacement in congenital adrenal hyperplasia.  Acta Endocr. 1986;  111 355-359
    PubMedGoogle Scholar
  • 38 Waldhauser F, Boepple P A, Schemper M, Mansfield M J, Crowley W F. Serum melatonin in central precocious puberty is lower than age-matched prepubertal children.  J Clin Endocrinol Metab. 1991;  73 793-796
    PubMedGoogle Scholar
  • 39 Wedell A. Molecular genetics of congenital adrenal hyperplasia (21-hydroxylase deficiency): implications for diagnosis, prognosis and treatment.  Acta Paediat. 1998;  87 159-164
    PubMedGoogle Scholar
  • 40 White P C, Speiser P W. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency.  Endocr Rev. 2000;  21 245-291
    CrossrefPubMedGoogle Scholar
  • 41 Woo M MM, Tai C J, Kang S K, Nathwani P S, Pang S F, Leung P CK. Direct action of melatonin in human granulosa-luteal cells.  J Clin Endocrinol Metab. 2001;  86 4789-4797
    CrossrefPubMedGoogle Scholar
  • 42 Yie S M, Niles L P, Younglai E V. Melatonin receptors on human granulosa cell membranes.  J Clin Endocrinol Metab. 1995;  80 1747-1749
    CrossrefPubMedGoogle Scholar

Prof. R. Luboshitzky

Endocrine Institute
Haemek Medical Center

18101 Afula

Israel

Phone: + 97246494354

Fax: + 9 72 46 49 55 53

Email: luboshitzky_r@clalit.org.il